Tag:
Protein Sciences
Latest Headlines
Latest Headlines
Zika update: Vaccine race swells, PaxVax CEO on how to stop 'chasing epidemics'
As the Zika virus continues to spread, more biotechs are announcing their Zika vaccine programs. Meriden, CT-based Protein Sciences, Atlanta-based GeoVax Labs and Redwood City, CA-based PaxVax are the latest. PaxVax plans to bring its candidate to animal trials during the first half of this year, CEO Nima Farzan told FierceVaccines.
Study: Flublok is more effective than traditional flu shot
Protein Sciences released data showing that Flublok Quadrivalent--its follow-up to the FDA-approved trivalent Flublok--outperformed the traditional egg-based quadrivalent vaccine.
Protein Sciences cancels expansion plans after governor gets flu shot from foreign competitor
Connecticut-based flu vaccine maker Protein Sciences has cancelled its expansion plans after learning the governor got his flu shot from a foreign competitor. The Meriden, CT-based company nixed negotiations to buy two local properties after hearing of Gov. Dannel Malloy's faux pas.
Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot
Flu vaccine maker Protein Sciences may be abandoning its expansion plans in Connecticut, opting instead to build out its New York-based manufacturing site. But it's not for any of the reasons one might expect.
Sanofi, Protein Sciences win flu jab nods in older adults
A couple of flu vaccine makers have new patient populations to target, thanks to a pair of recent FDA approvals in older adults.
Protein Sciences nabs stake in diabetes vax developer Diamyd
With its candidate diabetes vaccine in Phase II combo studies, Diamyd Medical is seeing some new investment--including a bumped-up agreement with longtime partner Protein Sciences.
Astellas and Takeda continue to advance vaccine strategies
Astellas presented summary results from Phase III trials of the Protein Sciences' flu shot it plans to commercialize in Japan. Separately, Takeda signed a deal to begin selling a freeze-dried live attenuated chickenpox vaccine in Japan.
Protein Sciences calls on Connecticut to buy its flu vaccine
The Connecticut-based biotech won approval for its flu vaccine last year but it faces competition from GlaxoSmithKline, Sanofi and the other established giants of the market.
Protein Sciences plans for battle with vaccine giants
After winning FDA approval for its influenza vaccine in January, Protein Sciences was faced with a problem: how to wrest market share from competitors. The task is complicated by the fact that, as yet, there is little evidence to show it is more effective than rivals.
Universal flu vaccine still 5 to 10 years away
Though the United States has made significant progress in the realm of flu vaccines, the country will likely need to wait 5 to 10 years for a universal shot, top federal health officials said.
